Pierre Triozzi to Dacarbazine
This is a "connection" page, showing publications Pierre Triozzi has written about Dacarbazine.
Connection Strength
0.791
-
Triozzi PL, Achberger S, Aldrich W, Singh AD, Grane R, Borden EC. The association of blood angioregulatory microRNA levels with circulating endothelial cells and angiogenic proteins in patients receiving dacarbazine and interferon. J Transl Med. 2012 Dec 05; 10:241.
Score: 0.427
-
Binkley E, Triozzi PL, Rybicki L, Achberger S, Aldrich W, Singh A. A prospective trial of adjuvant therapy for high-risk uveal melanoma: assessing 5-year survival outcomes. Br J Ophthalmol. 2020 04; 104(4):524-528.
Score: 0.169
-
Triozzi PL, Aldrich W. Effects of interleukin-1 receptor antagonist and chemotherapy on host-tumor interactions in established melanoma. Anticancer Res. 2010 Feb; 30(2):345-54.
Score: 0.088
-
Triozzi PL, Aldrich W, Dombos C. Differential effects of imatinib mesylate against uveal melanoma in vitro and in vivo. Melanoma Res. 2008 Dec; 18(6):420-30.
Score: 0.081
-
Yi T, Elson P, Mitsuhashi M, Jacobs B, Hollovary E, Budd TG, Spiro T, Triozzi P, Borden EC. Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects. Oncotarget. 2011 Dec; 2(12):1155-64.
Score: 0.025